Alivus Life Sciences is an Indian pharmaceutical company that makes high-value Active Pharmaceutical Ingredients - the biologically active molecules inside medicines - for chronic conditions like heart disease, diabetes and cancer, deliberately avoiding low-margin commodity chemicals. It was carved out in 2019 from Glenmark Pharmaceuticals, where it had operated as the in-house API division since 2001, and in March 2024 Nirma Limited acquired 75% ownership, removing legacy constraints and resetting the company on an independent growth path. The recurring approach is to pick molecules with high chemistry barriers and few competitors, develop patented synthetic routes, and build deep customer relationships that last a decade or more - a strategy of differentiation, not volume.
Business segments
A single engine - generic APIs for chronic diseases - that also feeds a small but growing contract manufacturing business, with both built on the same manufacturing and R&D backbone.
1. Generic APIs: the core engine
The company develops and sells complex, non-commoditised active pharmaceutical ingredients to the world's largest generic drug makers, with chronic therapies contributing two-thirds of revenue and regulated markets more than four-fifths.
- A portfolio of 176 molecules - the company has built a library of APIs spanning cardiovascular, central nervous system, diabetes, oncology, urology and pain management, up from 151 molecules as of FY24, with 8-10 new molecules added each year.
- Chronic therapies dominate - cardiovascular, CNS, diabetes and oncology products contributed 65% of revenue in the most recent quarter, while acute therapies made up the remaining 35%.
- Regulated markets are the anchor - 85% of revenue comes from regulated markets such as the US, Canada, Europe and Japan, where regulatory filings act as a moat; the company has filed 611 Drug Master Files and Certificates of Suitability across major markets to enable customers to use its APIs in their finished medicines.
- Deep customer relationships without contracts - the company serves roughly 900 customers across more than 75 countries, works with 20 of the largest generic companies globally, and has no long-term contracts, yet about 85% of revenue comes from relationships older than five years.
- Shifting toward higher-value customers - sales to non-Glenmark customers have grown from 59% to 71% of revenue over four years, a deliberate shift because the non-Glenmark business is structurally more profitable and value-accretive.
2. CDMO: contract manufacturing for innovators
The company makes specialty APIs on contract for innovator pharmaceutical companies, a business freed to grow now that the conflict of being part of a generic drug maker has been removed.
- Small but accelerating - the CDMO segment contributed 7% of revenue in the most recent fiscal year, up from 6% the year before, and saw a meaningful recovery in the second half of the year.
- Stickier, higher-margin work - specialty CDMO products are complex and customised, which means customers switch less often and margins are better than in the generic API business.
- Freed from legacy constraints - under Glenmark ownership, the CDMO business was limited by conflicts of interest with a global generic player; under Nirma, it can scale as an independent counterparty to innovator companies.
- Cyclical - the CDMO business was affected due to phasing of customer orders this quarter.
Manufacturing and R&D backbone
Four multi-purpose plants, three R&D centres and a large capacity expansion programme form the shared infrastructure that powers both the generic API and CDMO businesses.
- Four plants with 1,424 kilolitres of reactor capacity - the facilities at Ankleshwar, Dahej, Mohol and Kurkumbh can handle everything from kilograms to metric tonnes, and have been inspected 56 times by regulators including the USFDA, European and Japanese authorities.
- Three R&D centres plus one being built - existing centres at Mahape, Ankleshwar and Dahej focus on new molecule development, cost improvement and oncology respectively, while a new centre in Taloja will add capabilities in flow chemistry, particle engineering and green chemistry.
- Backward integration to protect margins - the company qualifies multiple vendors for raw materials across India and China and pursues in-house production of select key starting materials, with a dedicated 400-kilolitre backward-integration block planned at Solapur.
- Net cash and no long-term debt - the company has been net cash positive since FY19, carries no long-term borrowings, and held cash and equivalents of roughly ₹7,824 million at the end of March 2026, funding its expansion from internal accruals.
Group structure and partners
Alivus is a standalone public company with no subsidiaries, 75% owned by Nirma Limited, and governed by a seven-member board.
- Nirma is the promoter - the diversified Indian conglomerate acquired a 75% stake from Glenmark Pharmaceuticals in March 2024, bringing financial strength and long-term stability.
- No subsidiaries or joint ventures - the company operates as a single legal entity with no associate companies as defined under the Companies Act.
- Former Glenmark ties secured by contract - a five-year master supply agreement beginning April 2024 governs ongoing sales to Glenmark Pharmaceuticals, which submitted a request for reclassification from promoter to public shareholder.
- A small stake in renewable power - in April 2025 the company agreed to acquire a minimum 9.21% stake in Torrent Urja 19 Private Limited to qualify as a captive user under electricity regulations, aligned with a commitment to become carbon neutral by 2030.